Table 2.
Correlation of ERAP and HLA class I HC expression pattern with tumor subtype (A,C) and disease parameters (B, D)
| A | clear cell RCC | papillary RCC | chromophobe RCC | oncocytoma | total no of lesions |
|
| |||||
| ERAP1 downreg. | 15.1% (8/53) | 11.6% (5/43) | 7% (3/43) | 21.1% (4/19) | 158 |
| ERAP1 upreg. | 13.2% (7/53) | 30.2% (13/43) | 34.9% (15/43) | 5.3% (1/19) | |
| p = 0.057 chromophobe RCC vs. oncocytoma p = 0.022 | |||||
|
| |||||
|
| |||||
| ERAP2 downreg. | 50.0% (21/42) | 32.7% (16/49) | 75% (3/4) | 100% (3/3) | 98 |
| ERAP2 upreg. | 2.4% (1/42) | 2.0% (1/49) | 0% (0/4) | 0% (0/3) | |
| p = 0.190 | |||||
|
| |||||
|
| |||||
| B | UICC low stage (stage 1 + 2) | UICC high stage (stage 3 + 4) | low grade (grade 1 + 2) | high grade (grade 3 + 4) | total no of lesions |
|
| |||||
| ERAP1 downreg. | 9.3% (9/97) | 25% (6/24) | 10.7% (13/122) | 22.2% (4/18) | 121 (UICC stage) |
| ERAP1 upreg. | 22.7% (22/97) | 16.7% (4/24) | 25.4% (31/122) | 22.2% (4/18) | 140 (grade) |
| UICC stage p = 0.122; grade p = 0.450 | |||||
|
| |||||
|
| |||||
| ERAP2 downreg. | 35.8% (24/67) | 52.2% (12/23) | 42.9% (36/84) | 36.4% (4/11) | 90 (UICC stage) |
| ERAP2 upreg. | 3.0% (2/67) | 0% (0/23) | 2.4% (2/84) | 0% (0/11) | 95 (grade) |
| UICC stage p = 0.268; grade p = 0.807 | |||||
|
| |||||
|
| |||||
| C | clear cell RCC | papillary RCC | chromophobe RCC | oncocytoma | total no of lesions |
|
| |||||
| HLA class I HC loss/downreg. | 7.7% (4/52) | 11.1% (5/45) | 18.2% (2/11) | 0% (0/4) | 112 |
| HLA class I HC upreg. | 36.5% (19/52) | 15.6% (7/45) | 27.3% (3/11) | 25% (1/4) | |
| p = 0.322 | |||||
|
| |||||
|
| |||||
| D | UICC low stage (stage 1 + 2) | UICC high stage (stage 3 + 4) | low grade (grade 1 + 2) | high grade (grade 3 + 4) | total no of lesions |
|
| |||||
| HLA class I HC loss/downreg. | 9.2% (7/76) | 13% (3/23) | 11.5% (11/96) | 0% (0/12) | 99 (UICC stage) |
| HLA class I HC upreg. | 31.6% (24/76) | 13% (3/23) | 29.2% (28/96) | 8.3% (1/12) | 108 (grade) |
| UICC stage p = 0.240; grade p = 0.083 | |||||
Summary of the total number of tumor lesions analyzed for ERAP1, ERAP2 and HLA class I HC expression alterations (A, C) and their association with tumor stage and grade (B, D). Statistical test used: two-sided exact χ2-test (Pearson). P-values should be interpreted carefully due to the small amount of cases in the groups chromophobe, oncocytoma, high stage and high grade.